

Supplementary




Figure S1. Structures of PPOA derivatives, (A) acetamide A, (B) acetamide B, (C) acetamide C, and (D) acetamide D.




Figure S2. Cell viability assay. MTT assay was performed to determine cell viability using the indicated concentrations of PPOA-N-Ac-2-Cl for the indicated durations of time with M-CSF (30 ng/mL).




Figure S3. Quantification of the ratios of band intensity of p-ERK, p-JNK, p-P38, p-AKT, p-P65 and p-I κ B α relative to their total forms that total ERK, JNK, P38, AKT, P65 and I κ B α . Black bars indicate control, without PPOA-N-Ac-2-Cl treatment, and white bars indicate PPOA-N-Ac-2-Cl-treated group. * $p < 0.05$ versus the vehicle-treated control group.




Figure S4. Quantification of the ratios of band intensity of TRAF6, c-src, Calcineurin A, Calmodulin, c-fos, NFATc1 and CtsK relative to β-actin. Black bars indicate control, without PPOA-N-Ac-2-Cl treatment, and white bars indicate PPOA-N-Ac-2-Cl-treated group. * $p < 0.05$ versus the vehicle-treated control group.

Table S1. Primers used in the study.

Gene	Primer sequence (5' → 3')	
<i>Cathepsin K</i>	Forward	GGACGCAGCGATGCTAACTAA
	Reverse	CAGAGAGAACGGAAAGTAGAGTTGTCACT
<i>Acp5</i>	Forward	CAGCTGTCCTGGCTAAAAA
	Reverse	ACATAGCCCACACCGTTCTC
<i>DC-STAMP</i>	Forward	CGCACGATGCTTCATTCTTC
	Reverse	CAGTGCCAGCCGCAATC
<i>GAPDH</i>	Forward	TGTGTCCGTCGTGGATCTGA
	Reverse	GATGCCTGCTTCACCACCTT
<i>MMP9</i>	Forward	CTGGACAGCCAGACACTAAAG
	Reverse	CTCGCGCAAGTCTTCAGAG
<i>NFATc1</i>	Forward	ACCACCTTCCGCAACCA
	Reverse	GGTACTGGCTCTCTCCGTTTC
<i>ATP6v0d2</i>	Forward	GTGAGACCTTGGAAAGACCTGAAA
	Reverse	TCCTCATCTCCGTGTCATTG
<i>c-fos</i>	Forward	CGAAGGGAACGGAATAAGATG
	Reverse	GCTGCCAAAATAACTCCAG
<i>TRAF6</i>	Forward	TCGGACCTGGAGGACAA
	Reverse	CCAAACTTGCCAATCTCCAA